HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has announced its planned acquisition of the Kadima Neuropsychiatry Institute (Kadima) in La Jolla, California.
The financial terms of the transaction were not revealed.
The acquisition, announced in October last year, will expand the HOPE network of interventional psychiatry clinics. Kadima will become the flagship clinic in HOPE’s global network.
The network will offer advanced treatments for conditions like depression, anxiety, and post-traumatic stress disorder (PTSD).
Kadima is an interventional psychiatry clinic developing Ketamine Therapy for Central Nervous System (CNS) disorders.
Treatment options at Kadima include Ketamine Therapy, Spravato (nasal esketamine), Transcranial Magnetic Stimulation, and medication management.
Kadima is also a research hub, specialising in psychedelic research and serving as a site for clinical trials on new CNS treatments.
The clinic has established contracts with the US Department of Veterans Affairs and provides treatment to active-duty military personnel.
Kadima’s expertise will help guide HOPE Therapeutics’ expanding network, offering an integrated, multi-modal approach to treating these conditions.
Kadima founder and CEO David Feifel said: “In a world where nearly 60 million Americans suffer from a mental illness in any given year (ref), our dream has been to expand the successes and learnings of Kadima to an international stage, where we can continue to innovate and refine treatments that will create a world in which suicidal depression and PTSD are 100% treatable conditions, from which patients and their families should expect to return to empowered and productive lives.”
NRX is developing NRX-101, a US Food and Drug Administration (FDA)-designated Breakthrough Therapy for suicidal, treatment-resistant bipolar depression and chronic pain.
The company plans to file a new drug application (NDA) for accelerated approval for NRX-101 to treat bipolar depression with suicidality or akathisia. NRX-101 also shows potential as a non-opioid treatment for chronic pain and complicated UTIs.
Additionally, NRx plans to submit an NDA for NRX-100 (IV ketamine) for suicidal depression treatment. The asset has secured Fast Track Designation from the US FDA for treating acute suicidality.
HOPE Therapeutics co-CEOs Jonathan Javitt and Matthew Duffy said: “David has helped pioneer the field of interventional psychiatry and is one of the few global thought leaders who has been able to span the worlds of academia and community health care delivery, serving the residents of his community as well as active-duty military and veterans in a town known for hosting some of America’s most elite warriors.”
